Aim: Late-onset Pompe disease is characterized by progressive loss of muscular and respiratory
function. Until recently, standard of care was enzyme replacement therapy (ERT) with
alglucosidase alfa. Second-generation ERTs avalglucosidase alfa (aval) and ...